BD, Oxford Immunotec USA, Inc. and R & D Systems, Inc. are dominating the Asia-Pacific ELISpot and FluoroSpot Assay Market in 2020

Asia-Pacific Elispot and Fluorospot Assay Market is expected to grow with the CAGR of 15.5% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-fluorspot-and-elispot-assay-market

Asia-Pacific ELISpot and FluoroSpot assay market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenarios.

The major players dealing in Asia-Pacific ELISpot and FluoroSpot assay market are introducing a strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In April 2021, BD announced that the company will be presenting in virtual investor healthcare conferences “The Bank of America Securities 2021 Virtual Healthcare Conference” and ‘The UBS Asia-Pacific Healthcare Virtual Conference”. This helped company in gaining more customers Asia-Pacificly, and improved revenue for future market.

BD is the dominating player in Asia-Pacific ELISpot and FluoroSpot assay market. The other key players existing in the market are Thermo Fisher Scientific Inc., Mabtech, Cellular Technology Limited, CellCarta, DIACLONE SAS, Autoimmun Diagnostika GmbH, Oxford Biosystems, Oxford Immunotec USA, Inc., U-CyTech, MIKROGEN DIAGNOSTIK, Bio-Connect Diagnostics B.V, Covance Inc. Abcam plc. R & D Systems, Inc. and others.

Asia-Pacific ELISpot and FluoroSpot Assay MarketBD

BD is headquartered in New Jersey, U.S. and was founded in 1897. The company is engaged in the development, manufacturing and sale of wide range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company has many business segments like medical, life sciences and interventional, where life sciences segment is dominating segment. The company has several product & service categories including instruments, reagents, software & informatics, supplies, parts and setup reagents, services, custom solutions, blood collection, promotions in which reagents is the market focused category.

For instance,

  • In December 2017, BD announced that the company successfully acquired C. R. Bard, Inc. This strategic acquisition was done to improve both company’s diagnostics and treatment process for diseases to get better patient outcomes, thereby anticipated in improving company’s overall presence and income.

The company has wide presence across Americas, Asia-Pacific, Europe, and Middle East and Africa. The company also has various subsidiary companies including Accuri Cytometers, Inc. (Delaware), Accuri Cytometers (Europe), Ltd. (U.K.), Atto Bioscience, Inc. (Delaware), and B-D (U.K.) Ltd. (U.K.), among others.

Oxford Immunotec USA, Inc.

Oxford Immunotec USA Inc. was founded in the year 2002, and is headquartered in Oxford; U.K. Oxford Immunotec is an Asia-Pacific, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. The company is uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. The comp any operates its business via several business segments including diagnostics, discovery and analytical solutions in which diagnostics is the market focused segment.

  • In May 2021, Oxford Immunotec had declared the implementation of T-SPOT Discovery SARS-CoV-2 kit. The test kit was used for T cell testing in the UK COVID-19 Human Challenge Study. The first stage of the trial had commenced in March. The launch would provide a new platform for the ELISPOT methodology and portfolio and it would establish an optimised dose and study design that will subsequently be used to evaluate the efficacy of treatment and vaccine candidates.

The company has presence across Asia-Pacific, Europe, Middle East and Africa, South America, and Asia-Pacific. The company also has various subsidiaries including Oxford Immunotec (U.K.), IMUGEN, Inc (Massachusetts), Oxford Immunotec USA, Inc, Immunetics, Inc. (Massachusetts), and Boulder Diagnostics Inc. (Colorado) among others.

R & D Systems, Inc.

R & D Systems, Inc. was founded in the year 1976, and is headquartered in Minneapolis, USA. The company is engaged in producing hematology controls, calibrators, platelet-rich-plasma controls and being the second manufacturer in world to release world blood controls with platelets. The company has two product categories which are Recombinant Proteins, GMP Proteins, Antibodies, ELISAs, COmetAssay, Luminex Assays, Luminex Instruments, Cell Culture, Stem Cell Products, Small Molecules & Peptides, Enzyme, ELISpots, Cdna Clones, Flow Cytometry Workflow Solutions, Proteome Profiler Antibody in which ELISpots.

  • In March, R & D Systems, Inc. has announced that the company will be organizing their webinar session on arrays in cancer research. This webinar is focused on demonstrating their latest diagnostic kits and its application over cancer research thereby anticipated in enhancing the revenue for market.

The company has presence across Asia-Pacific, Europe, and Asia-Pacific.